Cannabinoid

True Terpenes' Science Advisory Board Chair Publishes Findings on Novel Extraction Technique

Thursday, October 21, 2021 - 1:00pm

"The True Terpenes Science Advisory Board is constantly seeking to learn more about terpenes and their therapeutic potential, while exploring methods in which we can reduce waste and impact on our environment," said Dr. Russo.

Key Points: 
  • "The True Terpenes Science Advisory Board is constantly seeking to learn more about terpenes and their therapeutic potential, while exploring methods in which we can reduce waste and impact on our environment," said Dr. Russo.
  • True Terpenes leads the industry in safety and compliance, and methods like Kryo-Kief demonstrate the company's forward-thinking approach to aromatic extraction.
  • Novel Solventless Extraction Technique to Preserve Cannabinoid and Terpenoid Profiles of Fresh Cannabis Inflorescence.
  • True Terpenes, a fully owned subsidiary of True Companies, is the industry-leading producer of effects-based, GMP/ISO/FSSC-certified terpenes and terpenoids blends.

GVB Biopharma Awarded Leading Manufacturer of the Year at 2021 NYC White Label Expo

Wednesday, October 20, 2021 - 8:00pm

NEW YORK, Oct. 20, 2021 /PRNewswire/ -- GVB Biopharma , the leader in hemp-derived cannabinoid active ingredient production and white label product formulation, announced today that it has been named Leading Manufacturer of the Year at the 2021 New York City White Label Expo .

Key Points: 
  • NEW YORK, Oct. 20, 2021 /PRNewswire/ -- GVB Biopharma , the leader in hemp-derived cannabinoid active ingredient production and white label product formulation, announced today that it has been named Leading Manufacturer of the Year at the 2021 New York City White Label Expo .
  • The award recognizes the outstanding manufacturer of white label products, which allow for rebranding by third parties.
  • The White Label Expo describes three selection criteria for its Leading Manufacturer of the Year Award recipient: a trusting relationship with their clients, an industry-leading quality control system and a seamless customer experience.
  • Three finalists were chosen, and GVB Biopharma was selected as the winner among more than 400 eligible companies.

International Technology Company Eybna Empowers the Next Generation of Wellness Products with Receptor-Specific™ Formulations

Wednesday, October 20, 2021 - 3:35pm

The core technology behind these formulations is the culmination of nearly a decade of scientific research and biological data analysis.

Key Points: 
  • The core technology behind these formulations is the culmination of nearly a decade of scientific research and biological data analysis.
  • Eybna will showcase their full line of products including the new Functional Line Receptor-Specific formulations at MJBizCon in Las Vegas from October 20-22.
  • For additional information on Eybna, its products, technology, science and white papers, please visit www.eybna.com or contact Avichai Elbaz at avichai@eybna.com .
  • Eybna is a pioneering technology company and terpene manufacturer with US HQ offices in California and R&D centers in Israel and Colorado.

Allied Corp Signs Major Supply Agreement With US Multi State Operator (MSO) and Sales Agreement for Allied’s CBD Brands

Wednesday, October 20, 2021 - 1:55pm

All of Allieds products are currently within the legal thresholds and within compliance of the national laws in the United States.

Key Points: 
  • All of Allieds products are currently within the legal thresholds and within compliance of the national laws in the United States.
  • We are ready to provide large volumes of high quality cannabis to the international marketplace.
  • With several supply contracts signed for the 2022 calendar year, we are ready to start shipping when Colombia allows.
  • Allied harvests on a weekly basis and by nature of this we believe that we will be able to provide rolling supply that is harvested fresh every week.

Blueberries Medical Corp Announces that its subsidiary Blueberries SAS has obtained the qualification as Breeding Unit and Exporter of Selected Seeds

Wednesday, October 20, 2021 - 12:30pm

TORONTO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the "Company" or "Blueberries"), a licensed Latin American producer of medical Cannabis and Cannabis-derived products, today announces that its wholly owned subsidiary Blueberries S.A.S.

Key Points: 
  • TORONTO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the "Company" or "Blueberries"), a licensed Latin American producer of medical Cannabis and Cannabis-derived products, today announces that its wholly owned subsidiary Blueberries S.A.S.
  • in Bogota, Colombia, obtained the registration of its agronomic operation area as a plant breeding unit and exporter of selected seeds.
  • The new capabilities of improving genetics and exporting seeds and cuttings are directly related with income generation and will help us to extend our sales streams internationally.
  • No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Cronos Group Launches its First Cultured Cannabinoid Product, SPINACH FEELZ™ Chill Bliss 2:1 THC|CBG Gummy

Wednesday, October 20, 2021 - 11:00am

SPINACH FEELZChill Bliss2:1 THC|CBG gummies arenow availablein the followingformat in Alberta, British Columbia, Manitoba, Ontario and Saskatchewan.

Key Points: 
  • SPINACH FEELZChill Bliss2:1 THC|CBG gummies arenow availablein the followingformat in Alberta, British Columbia, Manitoba, Ontario and Saskatchewan.
  • Today we mark an incredible achievement for Cronos Group and the cannabis industry at large with the launch of the first cannabis edible in Canada to feature cultured CBG.
  • This new product is truly a breakthrough in cannabis innovation, said Kurt Schmidt, President and CEO, Cronos Group.
  • The SPINACH FEELZChill Bliss gummy is Cronos Groups first consumer product created through the Companys partnership with Ginkgo Bioworks (Ginkgo).

Avicanna Closes Non-Brokered Private Placement Raising $3.9 Million and Announces Warrant Repricing

Tuesday, October 19, 2021 - 10:15pm

TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement (the "Offering"). Under the Offering, the Company has issued an aggregate of 4,587,022 units (the "Units") at a price of CAD$0.85 per Unit for aggregate gross proceeds of approximately CAD$3.9 million.

Key Points: 
  • Under the Offering, the Company has issued an aggregate of 4,587,022 units (the "Units") at a price of CAD$0.85 per Unit for aggregate gross proceeds of approximately CAD$3.9 million.
  • Each Unit is comprised of one (1) common share in the capital of the Company (each, a "Common Share") and one-half of one (0.5) common share purchase warrant (each whole warrant, a "Warrant").
  • Each Warrant is exercisable into one common share in the capital of the Company (each, a "Warrant Share") at a price of CAD$1.10 per Warrant Share for a period of three years from the closing of the Offering.
  • In connection with the closing of the Offering, the Company paid aggregate finder's fees of approximately $65,000 to eligible finders.

Delta 10 THC: Fresh Bros Announces How This Newly Discovered Cannabinoid Compares to Others on the Market

Tuesday, October 19, 2021 - 7:00pm

Delta 10 THC is a new cannabinoid that was discovered by a lucky mistake in California.

Key Points: 
  • Delta 10 THC is a new cannabinoid that was discovered by a lucky mistake in California.
  • Delta 10 Tetrahydrocannabinol (Delta 10 THC) is just one of over 150 known cannabinoids found in hemp and cannabis.
  • THC-O Acetate is reportedly way more potent than Delta 8 THC, Delta 10 THC, or even Delta 9 THC.
  • Fresh Bros sells the freshest organically grown hemp and CBD wholesale products from USA farms and laboratories, including Delta 10 THC.

Luna Technologies Introduces The Oberon Industrial-Grade Cannabis Extractor

Tuesday, October 19, 2021 - 4:00pm

Luna Technologies , a Portland-based manufacturer of hydrocarbon extraction equipment for the cannabis industry, today introduced the Oberon, a completely reimagined high-throughput hydrocarbon extractor with increased capacity to meet the needs of large-scale operators.

Key Points: 
  • Luna Technologies , a Portland-based manufacturer of hydrocarbon extraction equipment for the cannabis industry, today introduced the Oberon, a completely reimagined high-throughput hydrocarbon extractor with increased capacity to meet the needs of large-scale operators.
  • The system can also utilize an infinite number of programmable extraction recipes available through the Luna Technologies proprietary recipe book.
  • View the full release here: https://www.businesswire.com/news/home/20211019005518/en/
    Luna Technologies introduced the Oberon, a completely reimagined high-throughput hydrocarbon extractor that can process 36 pounds of fresh-frozen cannabis flower per hour, and more than 800 pounds per day.
  • (Photo: Business Wire)
    The introduction of the Oberon is our response to the unprecedented demand and increasing array of subcategory preferences in cannabis concentrates and extracts, said Jack Naito, president of Luna Technologies.

CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021

Tuesday, October 19, 2021 - 2:41pm

TEL AVIV, IsraelandBETHESDA, Md., Oct. 19, 2021 /PRNewswire/ --Cannabics Pharmaceuticals Inc. (OTC: CNBX),a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021, taking place today, Wednesday, October 19th.

Key Points: 
  • TEL AVIV, IsraelandBETHESDA, Md., Oct. 19, 2021 /PRNewswire/ --Cannabics Pharmaceuticals Inc. (OTC: CNBX),a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021, taking place today, Wednesday, October 19th.
  • Eyal Barad, Cannabics Pharmaceuticals Co-Founder and CEO said: "We are proud to have been selected to present at Edison's Open Forum Conference and share our perspective on synthetic cannabinoid drug development and on the challenges, opportunities and trends we see in the industry."
  • Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine.
  • For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.